Twist Bioscience Corporation Total Contract Liability
Twist Bioscience Corporation (TWST) had Total Contract Liability of $7.09 million as of 2026-03-31, per its 10-Q filed 2026-05-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-05-04
- 2026-03-31: Contract with Customer, Liability $7.09M.
- 2025-12-31: Contract with Customer, Liability $9.02M.
- 2025-09-30: Contract with Customer, Liability $6.88M.
- 2025-06-30: Contract with Customer, Liability $6.23M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2026-03-31 | $7.09M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $9.02M 10-Q/A · filed 2026-02-26 | |
| 2025-09-30 | $6.88M 10-Q · filed 2026-05-04 | |
| 2025-06-30 | $6.23M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $1.99M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $1.38M 10-Q · filed 2025-02-03 | |
| 2024-09-30 | $2.13M 10-K · filed 2025-11-17 | |
| 2024-06-30 | $2.90M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $2.50M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $2.60M 10-Q · filed 2024-02-02 | |
| 2023-09-30 | $3.00M 10-K · filed 2024-11-18 | $3.00M 10-K · filed 2023-11-21 |
| 2023-06-30 | $3.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $1.90M 10-Q · filed 2023-05-08 | |
| 2022-09-30 | $3.50M 10-K · filed 2023-11-21 | |
| 2021-09-30 | $1.10M 10-K/A · filed 2023-06-05 | |
| 2020-09-30 | $0.00 10-K · filed 2020-11-27 | |
| 2019-09-30 | $0.00 10-K · filed 2020-11-27 | |
| 2018-09-30 | $0.00 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |